Despite FDA's Letter to Merck Serono, Oral Cladribine is Still Expected to be the First Oral Disease-Modifying Therapy to Launch for Multiple Sclerosis in the United States
Advertisement
Novartis/Mitsubishi Tanabe's FTY-720 Remains on Track for Launch in Early 2011, According to Findings from Decision Resources
